Search Result

Results for "

RNA interference (RNAi)

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Small Interfering RNA (siRNA) (4) Complement System (1) Glycolate Oxidase (1) Lactate Dehydrogenase (2) Liposome (1)
By Research Areas:	Metabolic Disease (4)
Oligonucleotides:	Pegylated Lipids (1) siRNA drugs (4) siRNAs (4)

Inhibitors & Agonists

Biochemical Assay Reagents

Oligonucleotides

Targets Recommended: MicroRNA mRNA RNA MTase Small Interfering RNA (siRNA) DNA/RNA Synthesis Aminoacyl-tRNA Synthetase

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-112760

18:0 mPEG2000 PE sodium 1 Publications Verification DSPE-mPEG2000 sodium; 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] sodium	Liposome	Others
18:0 mPEG2000 PE (DSPE-mPEG2000) sodium is a conjugate of phospholipid and polyethylene glycol, and it can serve as an important PEG lipid component in lipid nanoparticles (LNPs). 18:0 mPEG2000 PE sodium can be used in the research of gene transfection, drug carriers and drug delivery .

HY-132606A

Nedosiran sodium DCR-PHXC sodium	Small Interfering RNA (siRNA) Lactate Dehydrogenase	Metabolic Disease
Nedosiran (DCR-PHXC) sodium is an RNA interference (RNAi) targeting lactate dehydrogenase (LDH). Nedosiran sodium represents an impactful potential therapeutic for primary hyperoxaluria (PH) with end-stage renal disease (ESRD). Nedosiran sodium is a GalNAc-dsRNA conjugate .

HY-132613

Lumasiran sodium	Small Interfering RNA (siRNA) Glycolate Oxidase	Metabolic Disease
Lumasiran sodium, an investigational RNA interference *(RNAi)* therapeutic agent, reduces hepatic oxalate production by targeting glycolate oxidase. Lumasiran sodium reduces urinary oxalate excretion, the cause of progressive kidney failure in primary hyperoxaluria type 1 (PH1) .

HY-145720

Cemdisiran ALN-CC5	Complement System Small Interfering RNA (siRNA)	Metabolic Disease
Cemdisiran (ALN-CC5) is an N-acetylgalactosamine-conjugated *RNAi* agent and also a complement component C5 inhibitor. Cemdisiran targets C5 mRNA, cleaves C5 mRNA via the endogenous RNA interference pathway, and inhibits the production of C5 protein in the liver. Cemdisiran exerts a dose-dependent inhibitory effect on total C5 concentrations in cynomolgus monkeys. When used in combination with Pozelimab (HY-P99786) in cynomolgus monkeys, Cemdisiran achieves a more sustained and complete inhibitory effect on complement activity. Cemdisiran can be used in the research of paroxysmal nocturnal hemoglobinuria and other complement-mediated diseases .

HY-132606

Nedosiran DCR-PHXC	Small Interfering RNA (siRNA) Lactate Dehydrogenase	Metabolic Disease
Nedosiran (DCR-PHXC) is an RNA interference (RNAi) targeting lactate dehydrogenase (LDH). Nedosiran represents an impactful potential therapeutic for primary hyperoxaluria (PH) with end-stage renal disease (ESRD). Nedosiran is a GalNAc-dsRNA conjugate .

Cat. No.	Product Name	Type

HY-112760

18:0 mPEG2000 PE sodium 1 Publications Verification DSPE-mPEG2000 sodium; 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] sodium	Biochemical Assay Reagents
18:0 mPEG2000 PE (DSPE-mPEG2000) sodium is a conjugate of phospholipid and polyethylene glycol, and it can serve as an important PEG lipid component in lipid nanoparticles (LNPs). 18:0 mPEG2000 PE sodium can be used in the research of gene transfection, drug carriers and drug delivery .

Cat. No.	Product Name		Classification

HY-112760

18:0 mPEG2000 PE sodium 1 Publications Verification DSPE-mPEG2000 sodium; 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] sodium		Pegylated Lipids
18:0 mPEG2000 PE (DSPE-mPEG2000) sodium is a conjugate of phospholipid and polyethylene glycol, and it can serve as an important PEG lipid component in lipid nanoparticles (LNPs). 18:0 mPEG2000 PE sodium can be used in the research of gene transfection, drug carriers and drug delivery .

HY-132606A

Nedosiran sodium DCR-PHXC sodium		siRNAs siRNA drugs
Nedosiran (DCR-PHXC) sodium is an RNA interference (RNAi) targeting lactate dehydrogenase (LDH). Nedosiran sodium represents an impactful potential therapeutic for primary hyperoxaluria (PH) with end-stage renal disease (ESRD). Nedosiran sodium is a GalNAc-dsRNA conjugate .

HY-132613

Lumasiran sodium		siRNAs siRNA drugs
Lumasiran sodium, an investigational RNA interference *(RNAi)* therapeutic agent, reduces hepatic oxalate production by targeting glycolate oxidase. Lumasiran sodium reduces urinary oxalate excretion, the cause of progressive kidney failure in primary hyperoxaluria type 1 (PH1) .

HY-145720

Cemdisiran ALN-CC5		siRNAs siRNA drugs
Cemdisiran (ALN-CC5) is an N-acetylgalactosamine-conjugated *RNAi* agent and also a complement component C5 inhibitor. Cemdisiran targets C5 mRNA, cleaves C5 mRNA via the endogenous RNA interference pathway, and inhibits the production of C5 protein in the liver. Cemdisiran exerts a dose-dependent inhibitory effect on total C5 concentrations in cynomolgus monkeys. When used in combination with Pozelimab (HY-P99786) in cynomolgus monkeys, Cemdisiran achieves a more sustained and complete inhibitory effect on complement activity. Cemdisiran can be used in the research of paroxysmal nocturnal hemoglobinuria and other complement-mediated diseases .

HY-132606

Nedosiran DCR-PHXC		siRNAs siRNA drugs
Nedosiran (DCR-PHXC) is an RNA interference (RNAi) targeting lactate dehydrogenase (LDH). Nedosiran represents an impactful potential therapeutic for primary hyperoxaluria (PH) with end-stage renal disease (ESRD). Nedosiran is a GalNAc-dsRNA conjugate .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
Email *

	Sorry, but the email address you supplied was invalid.